Cholecalciferol Supplementation for Sepsis in the ICU

NCT ID: NCT01896544

Last Updated: 2016-06-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-01-31
• Study Completion Date: 2014-12-31

Brief Summary

Sepsis in a clinical entity that occurs in patients with serious infections. Though the severity of illness may vary, every year, approximately 1.6 million Americans are treated for sepsis. Even with timely interventions, anywhere from 16% to >80% of patients with sepsis will not survive. Immune dysfunction is thought to play a critical role in the ability for infections to evolve into sepsis and to eventually lead to death. Recently, vitamin D has been identified as a key regulator of the immune system. While it remains unclear whether optimizing vitamin D status may improve outcomes in sepsis, little is known about the effects of vitamin D supplementation in patients with severe infections. As such, our goal is to study whether high doses of cholecalciferol (vitamin D3) can improve vitamin D status and boost certain aspects of the immune system in patients with sepsis.

Detailed Description

Sepsis is a clinical syndrome that complicates severe infections. It is characterized by the cardinal signs of inflammation (e.g. vasodilation, leukocytosis, increased microvascular permeability) occurring in tissues that are remote from the site of an infection. Current theories about the onset and progression of the sepsis syndrome focus on dysregulation of inflammatory responses, including the possibility that a massive and uncontrolled release of pro-inflammatory mediators initiates a chain of events that lead to widespread tissue injury. The degree of immune dysfunction is thought to correlate with the severity of the sepsis syndrome. Sepsis syndrome can range from sepsis, to severe sepsis, septic shock, and multiple organ dysfunction syndrome (MODS). The mortality associated with each of these is estimated to be 16%, 20%, 46%, >80%, respectively. The annual incidence of sepsis syndrome exceeds 1.6 million cases in the United States alone.

Recently, cells of the innate and adaptive immune system have been shown to express the vitamin D receptor. Vitamin D appears to be necessary for interferon-γ dependent T cell responses to infection. In low vitamin D states, dysfunctional macrophage activity becomes evident. Vitamin D is also an important link between Toll Like Receptor (TLR) activation and antibacterial response. Human macrophages stimulated by TLR induce: 1) vitamin D receptor expression; 2) conversion of 25(OH)D to its most biologically active form of 1,25-dihydroxyvitamin D; and 3) production of cathelicidin (LL-37), an endogenous antimicrobial peptide with potent activity against bacteria, viruses, fungi, and mycobacteria. LL-37 is highly expressed in both the plasma and at natural barrier sites (e.g. skin, gut, lungs) and may represent an important first-line of defense for the innate immune system.

In humans, cholecalciferol (vitamin D3) is either obtained through the diet or synthesized by skin upon exposure to ultraviolet B (UVB) radiation. Cholecalciferol is converted to 25(OH)D in the liver or by cells of the immune system. Serum 25(OH)D can be measured with relative ease and is the most abundant vitamin D metabolite. It is therefore, often used as a proxy for total body vitamin D status and 25(OH)D levels <30 ng/mL characterize an insufficient state. A growing body of evidence suggests that a significant proportion (50-90%) of critically ill patients may have insufficient 25(OH)D levels during admission to the intensive care unit (ICU). 25(OH)D insufficiency, in turn, appears to be associated with a higher risk of mortality in critically ill patients. However, randomized, placebo-controlled trials (RCTs) aimed at studying the effect of vitamin D supplementation in critical illness are limited and have largely focused on superficial assessments of vitamin D status. While it is known that septic patients have nearly universally low 25(OH)D levels and that the vitamin D levels are inversely correlated with the severity of sepsis, little is known regarding the effects of vitamin supplementation in this patient cohort. Therefore, our goal is to determine whether vitamin D supplementation in patients highly suspected of sepsis syndrome may be effective in optimizing 25(OH)D levels and in improving host production of the antimicrobial polypeptide LL-37.

Conditions

Hypovitaminosis D

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Cholecalciferol Dose II

Oral suspension cholecalciferol 400,000 IU

Group Type: ACTIVE_COMPARATOR

Cholecalciferol

Intervention Type: DIETARY_SUPPLEMENT

7ml syringe of cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube

Placebo

Oral suspension of placebo cholecalciferol

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DIETARY_SUPPLEMENT

7ml syringe of placebo cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube

Cholecalciferol Dose I

Oral suspension cholecalciferol 200,000 IU

Group Type: ACTIVE_COMPARATOR

Cholecalciferol

Intervention Type: DIETARY_SUPPLEMENT

7ml syringe of cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube

Interventions

Cholecalciferol

7ml syringe of cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube

Intervention Type: DIETARY_SUPPLEMENT

Placebo

7ml syringe of placebo cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• English or Spanish speaking
• Within 24 hours of a suspected diagnosis of sepsis
• Meeting criteria for sepsis (defined as suspected or confirmed infection AND at least one diagnostic criteria in each of the following groupings):

1. Vital signs:

1. Temperature: >38.3 Celsius (C) or <36 Celsius (C)

2. Heart rat e: >90/min, or >2 standard deviation above normal

3. Tachypnea (>20 breaths per minute)

4. Altered mental status

5. Positive fluid balance (>20 mL/Kg over 24 hrs)

6. Glucose >140 mg/dL in the absence of diabetes mellitus

2. Inflammatory markers:

1. white blood cell (WBC): >12,000 or <4,000

2. Normal WBC count with >10% immature forms

3. c-reactive protein (CRP) >2 standard deviation above normal value

4. Pro- calcitonin >2 standard deviation above normal value

3. Hemodynamic

1. Systolic blood pressure (SBP) <90 millimeters mercury (mmHg), Mean Arterial Pressure (MAP) <70mmHg or SBP decrease >40mmHg

2. Vasopressor therapy to maintain MAP >65mmHg

4. Organ dysfunction

1. Arterial hypoxemia arterial oxygen partial pressure/fractional inspired oxygen (PaO2/FiO2) <300

2. Acute Oliguria (UoP <0.5 mL/Kg/hr for at least 2 hours)

3. Cr increase >0.5 mg/dL

4. Coagulopathy: internationals normalized ratio (INR) >1.5 or a-partial prothrombin time (aPTT) >60 sec

5. Thrombocytopenia: Platelet (PLT) <100 thousand (K)

6. Hyperbilirubinemia: Total Bilirubin (Tbili) >4 mg/dL

5. Tissue perfusion

1. Lactate >2 mmol/L

2. Decrease cap refill or mottling

Exclusion Criteria

• Pregnant females or immediate post-partum status
• "Comfort measures only" status
• Inability to provide informed consent or have a surrogate consent
• History of renal stones within the past year
• History of hypercalcemia within the past year
• Baseline serum total calcium >10 mg/dL
• Established diagnosis associated with increased risk of hypercalcemia (e.g. metastatic cancer, sarcoidosis, multiple myeloma, primary hyperparathyroidism)
• History of severe anemia (Hematocrit <25%)
• Medications that affect vitamin D metabolism (e.g. antiepileptics, tuberculosis medication
• Already enrolled or planning to enroll in a research study that would conflict with full participation in the current study or confound the observation or interpretation of the study findings

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Massachusetts General Hospital

OTHER

Sponsor Role: lead

Responsible Party

Sadeq A. Quraishi

Assistant Professor of Anaesthesia, Harvard Medical School

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Sadeq A Quraishi, MD, MHA, MMSc

Role: PRINCIPAL_INVESTIGATOR

Harvard Medical School, Massachusetts General Hospital

Locations

Massachusetts General Hospital

Boston, Massachusetts, United States

Countries

United States

Other Identifiers

2013P001406

Identifier Type: -

Identifier Source: org_study_id